Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes

Maximilian Witzel, Daniel Petersheim, Yanxin Fan, Ehsan Bahrami, Tomas Racek, Meino Rohlfs, Jacek Puchałka, Christian Mertes, Julien Gagneur, Christoph Ziegenhain, Wolfgang Enard, Asbjørg Stray-Pedersen, Peter D. Arkwright, Miguel R. Abboud, Vahid Pazhakh, Graham J Lieschke, Peter M. Krawitz, Maik Dahlhoff, Marlon R. Schneider, Eckhard Wolf & 4 others Hans Peter Horny, Heinrich Schmidt, Alejandro A. Schäffer, Christoph Klein

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We identify SMARCD2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily D, member 2), also known as BAF60b (BRG1/Brahma-associated factor 60b), as a critical regulator of myeloid differentiation in humans, mice, and zebrafish. Studying patients from three unrelated pedigrees characterized by neutropenia, specific granule deficiency, myelodysplasia with excess of blast cells, and various developmental aberrations, we identified three homozygous loss-of-function mutations in SMARCD2. Using mice and zebrafish as model systems, we showed that SMARCD2 controls early steps in the differentiation of myeloid-erythroid progenitor cells. In vitro, SMARCD2 interacts with the transcription factor CEBPIϵ and controls expression of neutrophil proteins stored in specific granules. Defective expression of SMARCD2 leads to transcriptional and chromatin changes in acute myeloid leukemia (AML) human promyelocytic cells. In summary, SMARCD2 is a key factor controlling myelopoiesis and is a potential tumor suppressor in leukemia.

Original languageEnglish
Pages (from-to)742-752
Number of pages11
JournalNature Genetics
Volume49
Issue number5
DOIs
Publication statusPublished - 1 May 2017

Keywords

  • gene regulation
  • immunological deficiency syndromes
  • myelodysplastic syndrome
  • translational research

Cite this

Witzel, M., Petersheim, D., Fan, Y., Bahrami, E., Racek, T., Rohlfs, M., ... Klein, C. (2017). Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes. Nature Genetics, 49(5), 742-752. https://doi.org/10.1038/ng.3833
Witzel, Maximilian ; Petersheim, Daniel ; Fan, Yanxin ; Bahrami, Ehsan ; Racek, Tomas ; Rohlfs, Meino ; Puchałka, Jacek ; Mertes, Christian ; Gagneur, Julien ; Ziegenhain, Christoph ; Enard, Wolfgang ; Stray-Pedersen, Asbjørg ; Arkwright, Peter D. ; Abboud, Miguel R. ; Pazhakh, Vahid ; Lieschke, Graham J ; Krawitz, Peter M. ; Dahlhoff, Maik ; Schneider, Marlon R. ; Wolf, Eckhard ; Horny, Hans Peter ; Schmidt, Heinrich ; Schäffer, Alejandro A. ; Klein, Christoph. / Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes. In: Nature Genetics. 2017 ; Vol. 49, No. 5. pp. 742-752.
@article{5d42f68ea24f40f7a9aa5dd9b0983c72,
title = "Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes",
abstract = "We identify SMARCD2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily D, member 2), also known as BAF60b (BRG1/Brahma-associated factor 60b), as a critical regulator of myeloid differentiation in humans, mice, and zebrafish. Studying patients from three unrelated pedigrees characterized by neutropenia, specific granule deficiency, myelodysplasia with excess of blast cells, and various developmental aberrations, we identified three homozygous loss-of-function mutations in SMARCD2. Using mice and zebrafish as model systems, we showed that SMARCD2 controls early steps in the differentiation of myeloid-erythroid progenitor cells. In vitro, SMARCD2 interacts with the transcription factor CEBPIϵ and controls expression of neutrophil proteins stored in specific granules. Defective expression of SMARCD2 leads to transcriptional and chromatin changes in acute myeloid leukemia (AML) human promyelocytic cells. In summary, SMARCD2 is a key factor controlling myelopoiesis and is a potential tumor suppressor in leukemia.",
keywords = "gene regulation, immunological deficiency syndromes, myelodysplastic syndrome, translational research",
author = "Maximilian Witzel and Daniel Petersheim and Yanxin Fan and Ehsan Bahrami and Tomas Racek and Meino Rohlfs and Jacek Puchałka and Christian Mertes and Julien Gagneur and Christoph Ziegenhain and Wolfgang Enard and Asbj{\o}rg Stray-Pedersen and Arkwright, {Peter D.} and Abboud, {Miguel R.} and Vahid Pazhakh and Lieschke, {Graham J} and Krawitz, {Peter M.} and Maik Dahlhoff and Schneider, {Marlon R.} and Eckhard Wolf and Horny, {Hans Peter} and Heinrich Schmidt and Sch{\"a}ffer, {Alejandro A.} and Christoph Klein",
year = "2017",
month = "5",
day = "1",
doi = "10.1038/ng.3833",
language = "English",
volume = "49",
pages = "742--752",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "5",

}

Witzel, M, Petersheim, D, Fan, Y, Bahrami, E, Racek, T, Rohlfs, M, Puchałka, J, Mertes, C, Gagneur, J, Ziegenhain, C, Enard, W, Stray-Pedersen, A, Arkwright, PD, Abboud, MR, Pazhakh, V, Lieschke, GJ, Krawitz, PM, Dahlhoff, M, Schneider, MR, Wolf, E, Horny, HP, Schmidt, H, Schäffer, AA & Klein, C 2017, 'Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes' Nature Genetics, vol. 49, no. 5, pp. 742-752. https://doi.org/10.1038/ng.3833

Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes. / Witzel, Maximilian; Petersheim, Daniel; Fan, Yanxin; Bahrami, Ehsan; Racek, Tomas; Rohlfs, Meino; Puchałka, Jacek; Mertes, Christian; Gagneur, Julien; Ziegenhain, Christoph; Enard, Wolfgang; Stray-Pedersen, Asbjørg; Arkwright, Peter D.; Abboud, Miguel R.; Pazhakh, Vahid; Lieschke, Graham J; Krawitz, Peter M.; Dahlhoff, Maik; Schneider, Marlon R.; Wolf, Eckhard; Horny, Hans Peter; Schmidt, Heinrich; Schäffer, Alejandro A.; Klein, Christoph.

In: Nature Genetics, Vol. 49, No. 5, 01.05.2017, p. 742-752.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes

AU - Witzel, Maximilian

AU - Petersheim, Daniel

AU - Fan, Yanxin

AU - Bahrami, Ehsan

AU - Racek, Tomas

AU - Rohlfs, Meino

AU - Puchałka, Jacek

AU - Mertes, Christian

AU - Gagneur, Julien

AU - Ziegenhain, Christoph

AU - Enard, Wolfgang

AU - Stray-Pedersen, Asbjørg

AU - Arkwright, Peter D.

AU - Abboud, Miguel R.

AU - Pazhakh, Vahid

AU - Lieschke, Graham J

AU - Krawitz, Peter M.

AU - Dahlhoff, Maik

AU - Schneider, Marlon R.

AU - Wolf, Eckhard

AU - Horny, Hans Peter

AU - Schmidt, Heinrich

AU - Schäffer, Alejandro A.

AU - Klein, Christoph

PY - 2017/5/1

Y1 - 2017/5/1

N2 - We identify SMARCD2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily D, member 2), also known as BAF60b (BRG1/Brahma-associated factor 60b), as a critical regulator of myeloid differentiation in humans, mice, and zebrafish. Studying patients from three unrelated pedigrees characterized by neutropenia, specific granule deficiency, myelodysplasia with excess of blast cells, and various developmental aberrations, we identified three homozygous loss-of-function mutations in SMARCD2. Using mice and zebrafish as model systems, we showed that SMARCD2 controls early steps in the differentiation of myeloid-erythroid progenitor cells. In vitro, SMARCD2 interacts with the transcription factor CEBPIϵ and controls expression of neutrophil proteins stored in specific granules. Defective expression of SMARCD2 leads to transcriptional and chromatin changes in acute myeloid leukemia (AML) human promyelocytic cells. In summary, SMARCD2 is a key factor controlling myelopoiesis and is a potential tumor suppressor in leukemia.

AB - We identify SMARCD2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily D, member 2), also known as BAF60b (BRG1/Brahma-associated factor 60b), as a critical regulator of myeloid differentiation in humans, mice, and zebrafish. Studying patients from three unrelated pedigrees characterized by neutropenia, specific granule deficiency, myelodysplasia with excess of blast cells, and various developmental aberrations, we identified three homozygous loss-of-function mutations in SMARCD2. Using mice and zebrafish as model systems, we showed that SMARCD2 controls early steps in the differentiation of myeloid-erythroid progenitor cells. In vitro, SMARCD2 interacts with the transcription factor CEBPIϵ and controls expression of neutrophil proteins stored in specific granules. Defective expression of SMARCD2 leads to transcriptional and chromatin changes in acute myeloid leukemia (AML) human promyelocytic cells. In summary, SMARCD2 is a key factor controlling myelopoiesis and is a potential tumor suppressor in leukemia.

KW - gene regulation

KW - immunological deficiency syndromes

KW - myelodysplastic syndrome

KW - translational research

UR - http://www.scopus.com/inward/record.url?scp=85017020758&partnerID=8YFLogxK

U2 - 10.1038/ng.3833

DO - 10.1038/ng.3833

M3 - Article

VL - 49

SP - 742

EP - 752

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 5

ER -